Phase Ib proof-of-concept trial of ACH 3102 in patients with genotype 1a hepatitis C.

Trial Profile

Phase Ib proof-of-concept trial of ACH 3102 in patients with genotype 1a hepatitis C.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Odalasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 23 Apr 2013 Results reported at International Liver Congress 2013 at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL), according to an Achillion media release.
    • 03 Oct 2012 Status changed from recruiting to completed.
    • 07 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top